NCT02252185

Brief Summary

The primary objective of this study is to demonstrate that the efficacy and safety of Spine fusion system manufactured in China is no inferior than imported product.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
106

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2014

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 24, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 30, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

December 3, 2015

Status Verified

March 1, 2015

Enrollment Period

1.2 years

First QC Date

September 24, 2014

Last Update Submit

December 2, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of Japanese Orthopaedic Association score

    Questionnaire

    Preoperation and 24week post operation

Secondary Outcomes (4)

  • Improvement rate of Japanese Orthopaedic Association score

    7day, 12week, and 24week post operation

  • Fixation stability

    12week, and 24week post operation

  • Visual Analogue Score of low back and leg pain

    7day, 12week, and 24week post operation

  • Wound healing

    7day, 12week, and 24week post operation

Other Outcomes (1)

  • Adverse Events

    up to 24week post operation

Study Arms (2)

China made spine fusion system

EXPERIMENTAL

patents in this arm will be implanted with Johnson\&Johnson Medical Suzhou made Spine Fusion System.

Device: Johnson&Johnson Medical Suzhou made Spine Fusion System

Imported spine fusion system

ACTIVE COMPARATOR

patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .

Device: Imported EXPEDIUM screws and OPAL cage

Interventions

interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.

China made spine fusion system

Comparator in this study is active comparator.

Imported spine fusion system

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old, male or female;
  • Subject being diagnosed as having disc degeneration disease, spondylolisthesis, spinal fracture, deformity(degenerative deformity), spinal stenosis, or spinal tumor, has been treated with conservative treatment without relief or getting worse, who is suitable for surgery according to clinic practice.
  • Subject is a suitable candidate for implanting investigational products described in study protocols according to investigator's assessment;
  • Patient, in the opinion of the Clinical Investigator, is able to understand this clinical investigation and willing to be available for each required study procedure over the study duration.
  • Subject has been given voluntary, written informed consent to participate in this clinical investigation and has authorized the transfer of his/her information to study Sponsor.

You may not qualify if:

  • Patient has a local or systemic infection.
  • Patient has had one or more previous non-fusion spinal surgery at the involved level(s).
  • Patient without spinal deformity and requires fusion at 3 or more levels.
  • Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated
  • Has presence of active malignancy
  • Has a medical condition with less than 1 year of life expectancy.
  • Pregnancy or women in lactation period.
  • Is grossly obese, i.e. Body Mass Index≥40.
  • Has a diagnosis, which requires postoperative medication or treatment that interferes with fusion, such as steroids, chemotherapy, radiotherapy, growth factor (for more than 3 months), Nonsteroidal Antiinflammatory Drugs(for more than 3 months), and etc.
  • Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g. uncontrolled Diabetes with medication, renal osteodystrophy, or osteogenesis imperfect)
  • Alcoholic (taking more than 40g/day, equals to 100ml 50°Chinese liquor), smoking more than 40 cigarettes/day, or Drug abuser;
  • Is currently participating in another investigational drug or device study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Anhui Province Hospital

Hefei, Anhui, 230088, China

Location

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, 100035, China

Location

Henan Provincial People's Hospital

Zhengzhou, Henan, 450003, China

Location

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, 330006, China

Location

Shanghai Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

Location

Xijing Hospital

Xi’an, Shanxi, 710032, China

Location

The First Affiliated Hospital of Xi'an Jiaotong University Medical College

Xi’an, Shanxi, 710061, China

Location

The First Affiliated Hospital of Kunming Medical College

Kunming, Yunnan, 650032, China

Location

MeSH Terms

Conditions

Intervertebral Disc DegenerationSpondylolisthesisSpinal FracturesSpinal StenosisSpinal Cord Neoplasms

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal DiseasesSpondylolysisSpondylosisSpinal InjuriesBack InjuriesWounds and InjuriesFractures, BoneCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsSpinal Cord DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Wei Tian

    Beijing Jishuitan Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2014

First Posted

September 30, 2014

Study Start

July 1, 2014

Primary Completion

September 1, 2015

Study Completion

December 1, 2015

Last Updated

December 3, 2015

Record last verified: 2015-03

Locations